Abstract 425P
Background
The obesity survival paradox refers to the unexpected association of obesity with improved cancer survival outcomes. This phenomenon has been previously reported in IO treated solid tumor malignancies. We aimed to assess the impact of obesity on clinical outcomes in patients with advanced solid tumors treated with contemporary 1L IO based therapy.
Methods
Using the International Metastatic Renal Cell Carcinoma (RCC) Database Consortium and Alberta Immunotherapy Database, patients with advanced RCC, non-small cell lung cancer (NSCLC) or melanoma treated with 1L PD-(L)1 inhibition +/- tyrosine kinase inhibitor (RCC), chemotherapy (NSCLC) or CTLA-4 inhibitor (RCC/Melanoma) were included. As has been done in other analyses in the obesity paradox field, a comparison with obese (BMI ≥ 30.0 kg/m2) vs. normal weight (BMI 18.5-24.9 kg/m2) individuals was performed. Underweight (BMI < 18.5 kg/m2) patients (to avoid cachexia as a confounder) and overweight (BMI 25.0-29.9 kg/m2) patients (to not dilute the effect of obesity) were excluded. Objective response rate (ORR), time to treatment failure (TTF) and overall survival (OS) were calculated.
Results
Of 1067 patients, 30% and 33% of patients were found to be obese and normal weight, respectively. There were more males in obese vs. normal weight patients (66% vs. 55%, p<0.01). In NSCLC, PDL-1 expression was not different (p=0.39); and in RCC, there were less IMDC intermediate/poor risk patients among obese vs. normal weight patients (81% vs. 87%, p <0.01). In melanoma, there was no difference in BRAF status (p=0.68), LDH level (p=0.32), or metastatic burden (p=0.81) between obese vs. overweight patients. Overall, obese patients experienced a superior OS compared to normal weight patients (Table). Changing the BMI threshold to compare BMI ≥ 25 kg/m2 vs. normal weight yielded a similar result (median OS of 31.6 vs. 21.8 mons, p <0.01, respectively). Subgroup analysis by tumor type showed that the observed benefit was primarily driven by NSCLC. We were unable to detect a significant difference in OS among obese vs. normal weight patients with RCC or melanoma. In the RCC subgroup, there was a higher response rate in obese patients compared to normal weight patients. Table: 425P
Clinical outcomes of patients with obesity vs normal weight
Clinical outcome | Obesity | Normal weight | P-value |
Overall cohort (N=669) | N=316 | N=353 | - |
ORR %, (n/n) | 47% (125/265) | 40% (107/271) | 0.07 |
mTTF (mon) (95% CI) | 6.0 (4.9-7.5) | 4.8 (3.5-7.4) | 0.41 |
mOS (mon) (95% CI) | 32.2 (25.1-53.4) | 21.8 (16.3-28.1)) | 0.01 |
RCC (N=250) | N=140 | N=110 | - |
ORR | 47% (58/123) | 31% (28/90) | 0.02 |
mTTF | 7.6 (6.0-11.0) | 6.8 (3.0-9.6) | 0.86 |
mOS | 47.8 (29.6-57.8) | 30.9 (20.0-41.4) | 0.41 |
NSCLC (N=238) | N=84 | N=154 | - |
ORR | 35% (24/69) | 34% (38/112) | 0.90 |
mTTF | 5.8 (3.6-11.3) | 3.7 (2.7-4.9) | 0.20 |
mOS | 24.8 (18.5-28.3) | 8.6 (6.4-20.4) | 0.02 |
Melanoma (N=181) | N=92 | N=89 | - |
ORR | 59% (43/73) | 59% (41/69) | 0.95 |
mTTF | 4.6 (3.2-5.7) | 6.9 (2.9-10.8) | 0.48 |
mOS | 22.2 (13.0-NR) | 26.9 (18.9-NR) | 0.62 |
mTTF=median TTF, mOS=median OS
Conclusions
The obesity paradox exists in NSCLC. We are unable to demonstrate this finding in RCC, although the response rate was higher in obese patients. In melanoma, there was no difference in outcomes among obese vs. normal weight patients. The effect of obesity on treatment outcomes may be dependent on primary tumor type.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Daniel Y.C. Heng.
Funding
Has not received any funding.
Disclosure
J.C. Wells: Travel/Accommodation/Expenses: Pfizer. S.K. Pal: Advisory/Consultancy: Pfizer, Novartis, Aveo, Myriad Pharmaceuticals, Genentech, Exelixis, Bristol-Myers Squibb, Astellas Pharma, Ipsen, Eisai; Honoraria (self): Novartis, Medivation, Astellas Pharma; Research grant/Funding (institution): Medivation. F. Donskov: Research grant/Funding (institution): Pfizer, Ipsen. T.K. Choueiri: Advisory/Consultancy: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol-Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, Cerulean Pharma, AstraZeneca, Prometheus Laboratories, Alligent, Ipsen, Corvus Pharmaceuticals, Lpath, Alexion Pharmaceuticals, Sanofi/Aven; Leadership role: Dana Farber Cancer Hospital, NCCN, Kidney Cancer Association, KidneyCan, ASCO; Shareholder/Stockholder/Stock options: Pionyr, Tempest Therapeutics; Honoraria (institution): NCCN, UpToDate, Michael J. Hennessy Associates, ASCO, Harborside Press, Analysis Group, AstraZeneca, Alexion Pharmaceuticals, Sanofi/Aventis, Bayer, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Peloton Therapeutics, Pfizer, Cor; Research grant/Funding (institution): Pfizer, Novartis, Merck, Exelixis, Tracon Pharma, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, Peleton Therapeutics, Roche/Genentech, Celldex, Agensys, Eisai, Takeda, Prometheus, Ipsen, Corvus Phaarmaceuticals, Cerulean Pharma, Seatlle Genetics/Ast; Speaker Bureau/Expert testimony: Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel. D.Y.C. Heng: Advisory/Consultancy: Pfizer, Novartis, Bristol-Myers Squibb, Janssen, Astellas Pharma, Ipsen, Eisai, Merck; Research grant/Funding (institution): Pfizer, Novartis, Exelixis, Bristol-Myers Squibb, Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session